Rigel Pharmaceuticals (RIGL) Non-Current Debt (2019 - 2026)
Rigel Pharmaceuticals' (RIGL) quarterly Non-Current Debt came in at $15.0 million in Q1 2026, down 66.64% year-on-year from $44.9 million in Q1 2025, and down 71.33% quarter-over-quarter from $52.3 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Non-Current Debt (2019 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Non-Current Debt history runs 8 years deep, the most recent figure standing at $15.0 million for Q1 2026.
- On a quarterly basis, Non-Current Debt fell 66.64% year-over-year to $15.0 million in Q1 2026; TTM through Mar 2026 was $15.0 million, a 66.64% decrease from a year earlier, with the FY2025 full-year figure at $52.3 million, down 12.38% from the prior year.
- Non-Current Debt retreated to $15.0 million in Q1 2026 per RIGL's latest filing, from $52.3 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $59.8 million in Q3 2024 and bottomed at $15.0 million in Q1 2026.
- The 5-year median for Non-Current Debt is $44.9 million (2025), against an average of $45.5 million.
- Across the five-year window, Non-Current Debt soared 99.68% in 2023 and tumbled 66.64% in 2026, its largest moves.
- Year by year, Non-Current Debt stood at $39.4 million in 2022, then jumped by 32.76% to $52.4 million in 2023, then advanced by 13.95% to $59.7 million in 2024, then declined by 12.38% to $52.3 million in 2025, then sank by 71.33% to $15.0 million in 2026.
- Per Business Quant, the three latest RIGL Non-Current Debt figures stand at $15.0 million (Q1 2026), $52.3 million (Q4 2025), and $30.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Rigel Pharmaceuticals | 674.25 Mn | 527.57 Mn | 54.21 Mn | 14.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.99 Mn |
| Dec 31, 2025 | 52.29 Mn |
| Sep 30, 2025 | 29.97 Mn |
| Jun 30, 2025 | 37.45 Mn |
| Mar 31, 2025 | 44.93 Mn |
| Dec 31, 2024 | 59.68 Mn |
| Sep 30, 2024 | 59.76 Mn |
| Jun 30, 2024 | 59.69 Mn |
| Mar 31, 2024 | 44.91 Mn |
| Dec 31, 2023 | 52.37 Mn |
| Sep 30, 2023 | 59.66 Mn |
| Jun 30, 2023 | 59.57 Mn |
| Mar 31, 2023 | 59.48 Mn |
| Dec 31, 2022 | 39.45 Mn |
| Sep 30, 2022 | 39.47 Mn |
| Jun 30, 2022 | 29.84 Mn |
| Mar 31, 2022 | 29.85 Mn |
| Dec 31, 2021 | 19.91 Mn |
| Sep 30, 2021 | 19.89 Mn |
| Jun 30, 2021 | 19.86 Mn |